Antitumor effects of OAd5 are inhibited by pre-existing anti-Ad5 neutralizing antibodies, especially when the anti-Ad5 antibody titers are high or when the anti-Ad5 antibodies can easily access OAd5 before attachment to the tumor cells. The gene discussed is PSEN2; the disease is neoplasm.